Brodalumab: Six-Year US Pharmacovigilance Report
Pharmacovigilance data throughout 6 years are consistent with the safety profile of brodalumab established in clinical trials and previous US pharmacovigilance reports, with no completed suicides and a low fungal infection rate.
Authors
- Earl Goehring (ORCID: https://orcid.org/0000-0002-3935-8355)
- Abby Jacobson (ORCID: https://orcid.org/0000-0002-7810-2280)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Nicole Rawnsley (ORCID: https://orcid.org/0009-0005-7856-6615)
- Soo Han Yoon (ORCID: https://orcid.org/0000-0003-3685-668X)
- Bruce E Strober (ORCID: https://orcid.org/0000-0002-8394-2057)
- April W. Armstrong (ORCID: https://orcid.org/0000-0002-6892-6286)
- John Koo (ORCID: https://orcid.org/0009-0004-1005-5221)
- Gina D Mangin
Institutions
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- Yale University (US)
- Bausch Health (United States) (US)
- Central Dermatology (US)
- Dermatology Research Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1007/s13555-024-01304-y
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Ortho Dermatologics